Alcon Receives FDA Approval of Pazeo (olopatadine HCl) Ophthalmic Solution for Allergic Conjunctivitis

Basel, Switzerland, February 2, 2015 – Alcon, the global leader in eye care and a division of Novartis, has received approval from the U.S. Food and Drug Administration (FDA) of Pazeo (olopatadine hydrochloride ophthalmic solution) 0.7%, for the…
Drugs.com – New Drug Approvals

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us